HIGHLIGHTS
- who: CB and collaborators from the University of Lethbridge, Canada have published the paper: Chronic Administration of Cannabinoid Receptor 2 Agonist (JWH-133) Increases Ectopic Ovarian Tumor Growth and Endocannabinoids (Anandamide and 2-Arachidonoyl Glycerol) Levels in Immunocompromised SCID Female Mice, in the Journal: (JOURNAL)
- what: The authors will have the ectopic xenograft ovarian cancer cell grow a tumor for 30 days before the authors evaluate the impact of chronic administration of CB2 (JWH-133) agonist for 30 days and starting injection of JWH-133 after 30 days of tumor growth. The authors decided to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.